Solventum Co. (NYSE:SOLV) Given Average Recommendation of “Hold” by Analysts

Shares of Solventum Co. (NYSE:SOLV) have been given a consensus recommendation of “Hold” by the ten analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $64.33.

Several equities research analysts have commented on SOLV shares. BTIG Research started coverage on shares of Solventum in a research report on Thursday, September 5th. They set a “neutral” rating on the stock. Piper Sandler began coverage on Solventum in a report on Monday, October 7th. They set a “neutral” rating and a $71.00 target price on the stock. Morgan Stanley decreased their price target on Solventum from $70.00 to $55.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. Stifel Nicolaus began coverage on Solventum in a research note on Tuesday, October 8th. They set a “buy” rating and a $82.00 price objective on the stock. Finally, Wolfe Research started coverage on shares of Solventum in a research note on Thursday, September 26th. They issued a “peer perform” rating for the company.

Solventum Price Performance

SOLV stock opened at $72.59 on Friday. The business has a 50-day moving average of $68.68 and a 200-day moving average of $61.57. Solventum has a fifty-two week low of $47.16 and a fifty-two week high of $96.05. The company has a quick ratio of 0.96, a current ratio of 1.31 and a debt-to-equity ratio of 2.90.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, August 8th. The company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.10. The business had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.05 billion. The firm’s quarterly revenue was up .2% on a year-over-year basis. On average, equities analysts anticipate that Solventum will post 6.38 EPS for the current fiscal year.

Institutional Trading of Solventum

Hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD acquired a new stake in shares of Solventum during the first quarter worth $5,889,000. Mitsubishi UFJ Trust & Banking Corp acquired a new stake in Solventum in the 1st quarter worth about $5,747,000. CWM LLC bought a new stake in Solventum in the 2nd quarter valued at about $473,000. Great Valley Advisor Group Inc. acquired a new position in shares of Solventum during the 2nd quarter worth approximately $493,000. Finally, First Horizon Advisors Inc. bought a new position in shares of Solventum during the second quarter worth approximately $58,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.